Why Is Nano-Cap BioLineRx Stock Surging On Friday?
1. BLRX's Phase 2 trial shows promising results in pancreatic cancer treatment. 2. Pilot study demonstrates a 64% overall response rate using motixafortide combination. 3. Funding secured with a $10 million raise, extending the cash runway. 4. Company plans to significantly reduce operating expenses starting early 2025. 5. Jones Trading upgrades BLRX to 'Buy' with a $12 price target.